Australia markets open in 9 hours 14 minutes

Prescient Therapeutics Limited (PTX.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.0570-0.0020 (-3.39%)
At close: 04:10PM AEST

Prescient Therapeutics Limited

100 Albert Road
Level 4
Melbourne, VIC 3205
61 3 9692 7222

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Steven Lee Yatomi-ClarkeMD, CEO & Director595.35kN/AN/A
Ms. Melanie Jaye Leydin B.Bus, C.A.CFO & Company Secretary158.4kN/A1973
Ms. Leanne WestDirector of Clinical Affairs & OperationsN/AN/AN/A
Dr. Terrence G. ChewChief Medical Officer155.99kN/A1947
Ms. Rebecca LimSenior Vice President of Scientific AffairsN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. The company was incorporated in 1986 and is based in Melbourne, Australia.

Corporate governance

Prescient Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.